Core Viewpoint - Agios Pharmaceuticals has received FDA approval for mitapivat, a treatment for anemia in adults with alpha or beta thalassemia, which will be marketed as AQVESME in the United States [2]. Group 1: FDA Approval - The FDA has approved mitapivat for treating anemia in adults with alpha or beta thalassemia [2]. - The drug will be marketed under the brand name AQVESME in the United States [2]. Group 2: Investor Relations - Morgan Sanford, Vice President of Investor Relations, is leading the conference call to discuss the approval and its implications [2]. - The company has provided access to presentation slides on its website for investors [2].

Key Points The new indication is relatively rare in the U.S., but pricing is substantial, and the need for the treatment is significant. The positive update turns the company's fortunes around after a disappointing update earlier in the year. 10 stocks we like better than Agios Pharmaceuticals › Shares in Agios Pharmaceuticals (NASDAQ: AGIO) soared by more than 18% as of 11 a.m. today. The move follows the company's receipt of approval from the Food and Drug Administration (FDA) for AQVESME (mitapiv ...